Selected research
Market Structure
Global Cystic Fibrosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Cystic Fibrosis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Cystic Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cystic Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cystic Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Cystic Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Cystic Fibrosis Drugs include Abbott, Johnson & Johnson, Novartis, Vertex Pharmaceuticals, Venus Remedies, United Medical, PTC Therapeutics, Proteostasis Therapeutics and Pharmaxis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Cystic Fibrosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cystic Fibrosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cystic Fibrosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cystic Fibrosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Cystic Fibrosis Drugs Segment by Company
Abbott
Johnson & Johnson
Novartis
Vertex Pharmaceuticals
Venus Remedies
United Medical
PTC Therapeutics
Proteostasis Therapeutics
Pharmaxis
PharmaSwiss
Novo Nordisk
Neovii Biotech
Merck Sharp & Dohme
Insmed
Gilead Sciences
Genzyme
F. Hoffmann-La Roche
Corbus Pharmaceuticals
Chiesi Farmaceutici
Boehringer Ingelheim
Arcturus Therapeutics
Anthera Pharmaceuticals
Actavis
Cystic Fibrosis Drugs Segment by Type
Oral Cystic Fibrosis Drugs
Injection Cystic Fibrosis Drugs
Cystic Fibrosis Drugs Segment by Application
Hospitals
Clinics
Other
Cystic Fibrosis Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cystic Fibrosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cystic Fibrosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cystic Fibrosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Cystic Fibrosis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cystic Fibrosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cystic Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Cystic Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Cystic Fibrosis Drugs Industry Trends
Table 2. Cystic Fibrosis Drugs Industry Drivers
Table 3. Cystic Fibrosis Drugs Industry Opportunities and Challenges
Table 4. Cystic Fibrosis Drugs Industry Restraints
Table 5. Global Cystic Fibrosis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Cystic Fibrosis Drugs Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Cystic Fibrosis Drugs Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Cystic Fibrosis Drugs Sales Market Share by Manufacturers
Table 9. Global Cystic Fibrosis Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Cystic Fibrosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Cystic Fibrosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Cystic Fibrosis Drugs Manufacturers, Product Type & Application
Table 13. Global Cystic Fibrosis Drugs Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Cystic Fibrosis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Oral Cystic Fibrosis Drugs
Table 17. Major Manufacturers of Injection Cystic Fibrosis Drugs
Table 18. Global Cystic Fibrosis Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 19. Global Cystic Fibrosis Drugs Sales by Type (2021-2026) & (K Units)
Table 20. Global Cystic Fibrosis Drugs Sales by Type (2027-2032) & (K Units)
Table 21. Global Cystic Fibrosis Drugs Sales Market Share by Type (2021-2026)
Table 22. Global Cystic Fibrosis Drugs Sales Market Share by Type (2027-2032)
Table 23. Global Cystic Fibrosis Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 24. Global Cystic Fibrosis Drugs Revenue by Type (2021-2026) & (K Units)
Table 25. Global Cystic Fibrosis Drugs Revenue by Type (2027-2032) & (K Units)
Table 26. Global Cystic Fibrosis Drugs Revenue Market Share by Type (2021-2026)
Table 27. Global Cystic Fibrosis Drugs Revenue Market Share by Type (2027-2032)
Table 28. Major Manufacturers of Hospitals
Table 29. Major Manufacturers of Clinics
Table 30. Major Manufacturers of Other
Table 31. Global Cystic Fibrosis Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 32. Global Cystic Fibrosis Drugs Sales by Application (2021-2026) & (K Units)
Table 33. Global Cystic Fibrosis Drugs Sales by Application (2027-2032) & (K Units)
Table 34. Global Cystic Fibrosis Drugs Sales Market Share by Application (2021-2026)
Table 35. Global Cystic Fibrosis Drugs Sales Market Share by Application (2027-2032)
Table 36. Global Cystic Fibrosis Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 37. Global Cystic Fibrosis Drugs Revenue by Application (2021-2026) & (K Units)
Table 38. Global Cystic Fibrosis Drugs Revenue by Application (2027-2032) & (K Units)
Table 39. Global Cystic Fibrosis Drugs Revenue Market Share by Application (2021-2026)
Table 40. Global Cystic Fibrosis Drugs Revenue Market Share by Application (2027-2032)
Table 41. Global Cystic Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 42. Global Cystic Fibrosis Drugs Sales by Region (2021-2026) & (K Units)
Table 43. Global Cystic Fibrosis Drugs Sales Market Share by Region (2021-2026)
Table 44. Global Cystic Fibrosis Drugs Sales Forecasted by Region (2027-2032) & (K Units)
Table 45. Global Cystic Fibrosis Drugs Sales Forecasted Market Share by Region (2027-2032)
Table 46. North America Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 47. North America Cystic Fibrosis Drugs Sales by Country (2021-2026) & (K Units)
Table 48. North America Cystic Fibrosis Drugs Sales by Country (2027-2032) & (K Units)
Table 49. Europe Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 50. Europe Cystic Fibrosis Drugs Sales by Country (2021-2026) & (K Units)
Table 51. Europe Cystic Fibrosis Drugs Sales by Country (2027-2032) & (K Units)
Table 52. Asia Pacific Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 53. Asia Pacific Cystic Fibrosis Drugs Sales by Country (2021-2026) & (K Units)
Table 54. Asia Pacific Cystic Fibrosis Drugs Sales by Country (2027-2032) & (K Units)
Table 55. South America, Middle East and Africa Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 56. South America, Middle East and Africa Cystic Fibrosis Drugs Sales by Country (2021-2026) & (K Units)
Table 57. South America, Middle East and Africa Cystic Fibrosis Drugs Sales by Country (2027-2032) & (K Units)
Table 58. Global Cystic Fibrosis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 59. Global Cystic Fibrosis Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 60. Global Cystic Fibrosis Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 61. Global Cystic Fibrosis Drugs Revenue Market Share by Region (2021-2026)
Table 62. Global Cystic Fibrosis Drugs Revenue Market Share by Region (2027-2032)
Table 63. Abbott Company Information
Table 64. Abbott Business Overview
Table 65. Abbott Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 66. Abbott Cystic Fibrosis Drugs Product Portfolio
Table 67. Abbott Recent Development
Table 68. Johnson & Johnson Company Information
Table 69. Johnson & Johnson Business Overview
Table 70. Johnson & Johnson Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Johnson & Johnson Cystic Fibrosis Drugs Product Portfolio
Table 72. Johnson & Johnson Recent Development
Table 73. Novartis Company Information
Table 74. Novartis Business Overview
Table 75. Novartis Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 76. Novartis Cystic Fibrosis Drugs Product Portfolio
Table 77. Novartis Recent Development
Table 78. Vertex Pharmaceuticals Company Information
Table 79. Vertex Pharmaceuticals Business Overview
Table 80. Vertex Pharmaceuticals Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 81. Vertex Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
Table 82. Vertex Pharmaceuticals Recent Development
Table 83. Venus Remedies Company Information
Table 84. Venus Remedies Business Overview
Table 85. Venus Remedies Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 86. Venus Remedies Cystic Fibrosis Drugs Product Portfolio
Table 87. Venus Remedies Recent Development
Table 88. United Medical Company Information
Table 89. United Medical Business Overview
Table 90. United Medical Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 91. United Medical Cystic Fibrosis Drugs Product Portfolio
Table 92. United Medical Recent Development
Table 93. PTC Therapeutics Company Information
Table 94. PTC Therapeutics Business Overview
Table 95. PTC Therapeutics Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 96. PTC Therapeutics Cystic Fibrosis Drugs Product Portfolio
Table 97. PTC Therapeutics Recent Development
Table 98. Proteostasis Therapeutics Company Information
Table 99. Proteostasis Therapeutics Business Overview
Table 100. Proteostasis Therapeutics Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 101. Proteostasis Therapeutics Cystic Fibrosis Drugs Product Portfolio
Table 102. Proteostasis Therapeutics Recent Development
Table 103. Pharmaxis Company Information
Table 104. Pharmaxis Business Overview
Table 105. Pharmaxis Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 106. Pharmaxis Cystic Fibrosis Drugs Product Portfolio
Table 107. Pharmaxis Recent Development
Table 108. PharmaSwiss Company Information
Table 109. PharmaSwiss Business Overview
Table 110. PharmaSwiss Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 111. PharmaSwiss Cystic Fibrosis Drugs Product Portfolio
Table 112. PharmaSwiss Recent Development
Table 113. Novo Nordisk Company Information
Table 114. Novo Nordisk Business Overview
Table 115. Novo Nordisk Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 116. Novo Nordisk Cystic Fibrosis Drugs Product Portfolio
Table 117. Novo Nordisk Recent Development
Table 118. Neovii Biotech Company Information
Table 119. Neovii Biotech Business Overview
Table 120. Neovii Biotech Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 121. Neovii Biotech Cystic Fibrosis Drugs Product Portfolio
Table 122. Neovii Biotech Recent Development
Table 123. Merck Sharp & Dohme Company Information
Table 124. Merck Sharp & Dohme Business Overview
Table 125. Merck Sharp & Dohme Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 126. Merck Sharp & Dohme Cystic Fibrosis Drugs Product Portfolio
Table 127. Merck Sharp & Dohme Recent Development
Table 128. Insmed Company Information
Table 129. Insmed Business Overview
Table 130. Insmed Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 131. Insmed Cystic Fibrosis Drugs Product Portfolio
Table 132. Insmed Recent Development
Table 133. Gilead Sciences Company Information
Table 134. Gilead Sciences Business Overview
Table 135. Gilead Sciences Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 136. Gilead Sciences Cystic Fibrosis Drugs Product Portfolio
Table 137. Gilead Sciences Recent Development
Table 138. Genzyme Company Information
Table 139. Genzyme Business Overview
Table 140. Genzyme Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 141. Genzyme Cystic Fibrosis Drugs Product Portfolio
Table 142. Genzyme Recent Development
Table 143. F. Hoffmann-La Roche Company Information
Table 144. F. Hoffmann-La Roche Business Overview
Table 145. F. Hoffmann-La Roche Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 146. F. Hoffmann-La Roche Cystic Fibrosis Drugs Product Portfolio
Table 147. F. Hoffmann-La Roche Recent Development
Table 148. Corbus Pharmaceuticals Company Information
Table 149. Corbus Pharmaceuticals Business Overview
Table 150. Corbus Pharmaceuticals Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 151. Corbus Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
Table 152. Corbus Pharmaceuticals Recent Development
Table 153. Chiesi Farmaceutici Company Information
Table 154. Chiesi Farmaceutici Business Overview
Table 155. Chiesi Farmaceutici Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 156. Chiesi Farmaceutici Cystic Fibrosis Drugs Product Portfolio
Table 157. Chiesi Farmaceutici Recent Development
Table 158. Boehringer Ingelheim Company Information
Table 159. Boehringer Ingelheim Business Overview
Table 160. Boehringer Ingelheim Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 161. Boehringer Ingelheim Cystic Fibrosis Drugs Product Portfolio
Table 162. Boehringer Ingelheim Recent Development
Table 163. Arcturus Therapeutics Company Information
Table 164. Arcturus Therapeutics Business Overview
Table 165. Arcturus Therapeutics Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 166. Arcturus Therapeutics Cystic Fibrosis Drugs Product Portfolio
Table 167. Arcturus Therapeutics Recent Development
Table 168. Anthera Pharmaceuticals Company Information
Table 169. Anthera Pharmaceuticals Business Overview
Table 170. Anthera Pharmaceuticals Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 171. Anthera Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
Table 172. Anthera Pharmaceuticals Recent Development
Table 173. Actavis Company Information
Table 174. Actavis Business Overview
Table 175. Actavis Cystic Fibrosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 176. Actavis Cystic Fibrosis Drugs Product Portfolio
Table 177. Actavis Recent Development
Table 178. Key Raw Materials
Table 179. Raw Materials Key Suppliers
Table 180. Cystic Fibrosis Drugs Distributors List
Table 181. Cystic Fibrosis Drugs Customers List
Table 182. Research Programs/Design for This Report
Table 183. Authors List of This Report
Table 184. Secondary Sources
Table 185. Primary Sources
List of Figures
Figure 1. Cystic Fibrosis Drugs Product Image
Figure 2. Global Cystic Fibrosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Cystic Fibrosis Drugs Market Size (2021-2032) & (US$ Million)
Figure 4. Global Cystic Fibrosis Drugs Sales (2021-2032) & (K Units)
Figure 5. Global Cystic Fibrosis Drugs Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Cystic Fibrosis Drugs Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Oral Cystic Fibrosis Drugs Image
Figure 9. Injection Cystic Fibrosis Drugs Image
Figure 10. Global Cystic Fibrosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 11. Global Cystic Fibrosis Drugs Sales Market Share 2021 VS 2025 VS 2032
Figure 12. Global Cystic Fibrosis Drugs Sales Market Share by Type (2021-2032)
Figure 13. Global Cystic Fibrosis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 14. Global Cystic Fibrosis Drugs Revenue Market Share 2021 VS 2025 VS 2032
Figure 15. Global Cystic Fibrosis Drugs Revenue Market Share by Type (2021-2032)
Figure 16. Hospitals Image
Figure 17. Clinics Image
Figure 18. Other Image
Figure 19. Global Cystic Fibrosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 20. Global Cystic Fibrosis Drugs Sales Market Share 2021 VS 2025 VS 2032
Figure 21. Global Cystic Fibrosis Drugs Sales Market Share by Application (2021-2032)
Figure 22. Global Cystic Fibrosis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 23. Global Cystic Fibrosis Drugs Revenue Market Share 2021 VS 2025 VS 2032
Figure 24. Global Cystic Fibrosis Drugs Revenue Market Share by Application (2021-2032)
Figure 25. North America Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 26. North America Cystic Fibrosis Drugs Sales Market Share by Country (2021-2032)
Figure 27. U.S. Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 28. Canada Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 29. Mexico Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 30. Europe Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 31. Europe Cystic Fibrosis Drugs Sales Market Share by Country (2021-2032)
Figure 32. Germany Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 33. France Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 34. U.K. Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 35. Italy Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 36. Netherlands Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 37. Asia Pacific Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. Asia Pacific Cystic Fibrosis Drugs Sales Market Share by Country (2021-2032)
Figure 39. China Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 40. Japan Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 41. South Korea Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 42. Southeast Asia Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 43. India Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 44. Australia Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. South America, Middle East and Africa Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. South America, Middle East and Africa Cystic Fibrosis Drugs Sales Market Share by Country (2021-2032)
Figure 47. Brazil Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 48. South Africa Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 49. Saudi Arabia Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 50. Turkey Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 51. Argentina Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 52. UAE Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. Egypt Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. Chile Cystic Fibrosis Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. Global Cystic Fibrosis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 56. Global Cystic Fibrosis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 57. North America Cystic Fibrosis Drugs Revenue (2021-2032) & (US$ Million)
Figure 58. North America Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 59. Europe Cystic Fibrosis Drugs Revenue (2021-2032) & (US$ Million)
Figure 60. Europe Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 61. Asia-Pacific Cystic Fibrosis Drugs Revenue (2021-2032) & (US$ Million)
Figure 62. Asia-Pacific Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 63. South America, Middle East and Africa Cystic Fibrosis Drugs Revenue (2021-2032) & (US$ Million)
Figure 64. South America, Middle East and Africa Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 65. Cystic Fibrosis Drugs Value Chain
Figure 66. Manufacturing Cost Structure
Figure 67. Cystic Fibrosis Drugs Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. Years Considered
Figure 71. Research Process
Figure 72. Key Executives Interviewed
Scope & coverage.
Types
- Oral Cystic Fibrosis Drugs
- Injection Cystic Fibrosis Drugs
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Abbott
- Johnson & Johnson
- Novartis
- Vertex Pharmaceuticals
- Venus Remedies
- United Medical
- PTC Therapeutics
- Proteostasis Therapeutics
- Pharmaxis
- PharmaSwiss
- Novo Nordisk
- Neovii Biotech
- Merck Sharp & Dohme
- Insmed
- Gilead Sciences
- Genzyme
- F. Hoffmann-La Roche
- Corbus Pharmaceuticals
- Chiesi Farmaceutici
- Boehringer Ingelheim
- Arcturus Therapeutics
- Anthera Pharmaceuticals
- Actavis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cystic Fibrosis Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cystic Fibrosis Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Cystic Fibrosis Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Cystic Fibrosis Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Cystic Fibrosis Drugs Market Dynamics
- 2.1 Cystic Fibrosis Drugs Industry Trends
- 2.2 Cystic Fibrosis Drugs Industry Drivers
- 2.3 Cystic Fibrosis Drugs Industry Opportunities and Challenges
- 2.4 Cystic Fibrosis Drugs Industry Restraints
3 Cystic Fibrosis Drugs Market by Manufacturers
- 3.1 Global Cystic Fibrosis Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Cystic Fibrosis Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Cystic Fibrosis Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Cystic Fibrosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Cystic Fibrosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Cystic Fibrosis Drugs Manufacturers, Product Type & Application
- 3.7 Global Cystic Fibrosis Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Cystic Fibrosis Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Cystic Fibrosis Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Cystic Fibrosis Drugs Tier 1, Tier 2, and Tier 3
4 Cystic Fibrosis Drugs Market by Type
- 4.1 Cystic Fibrosis Drugs Type Introduction
- 4.1.1 Oral Cystic Fibrosis Drugs
- 4.1.2 Injection Cystic Fibrosis Drugs
- 4.2 Global Cystic Fibrosis Drugs Sales by Type
- 4.2.1 Global Cystic Fibrosis Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cystic Fibrosis Drugs Sales by Type (2021-2032)
- 4.2.3 Global Cystic Fibrosis Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Cystic Fibrosis Drugs Revenue by Type
- 4.3.1 Global Cystic Fibrosis Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Cystic Fibrosis Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Cystic Fibrosis Drugs Revenue Market Share by Type (2021-2032)
5 Cystic Fibrosis Drugs Market by Application
- 5.1 Cystic Fibrosis Drugs Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Clinics
- 5.1.3 Other
- 5.2 Global Cystic Fibrosis Drugs Sales by Application
- 5.2.1 Global Cystic Fibrosis Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cystic Fibrosis Drugs Sales by Application (2021-2032)
- 5.2.3 Global Cystic Fibrosis Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Cystic Fibrosis Drugs Revenue by Application
- 5.3.1 Global Cystic Fibrosis Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Cystic Fibrosis Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Cystic Fibrosis Drugs Revenue Market Share by Application (2021-2032)
6 Global Cystic Fibrosis Drugs Sales by Region
- 6.1 Global Cystic Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cystic Fibrosis Drugs Sales by Region (2021-2032)
- 6.2.1 Global Cystic Fibrosis Drugs Sales by Region (2021-2026)
- 6.2.2 Global Cystic Fibrosis Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Cystic Fibrosis Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Cystic Fibrosis Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Cystic Fibrosis Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Cystic Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Cystic Fibrosis Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Cystic Fibrosis Drugs Revenue by Region
- 7.1 Global Cystic Fibrosis Drugs Revenue by Region
- 7.1.1 Global Cystic Fibrosis Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Cystic Fibrosis Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Cystic Fibrosis Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Cystic Fibrosis Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Cystic Fibrosis Drugs Revenue (2021-2032)
- 7.2.2 North America Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Cystic Fibrosis Drugs Revenue (2021-2032)
- 7.3.2 Europe Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Cystic Fibrosis Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Cystic Fibrosis Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Cystic Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Abbott
- 8.1.1 Abbott Company Information
- 8.1.2 Abbott Business Overview
- 8.1.3 Abbott Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Abbott Cystic Fibrosis Drugs Product Portfolio
- 8.1.5 Abbott Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Company Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Cystic Fibrosis Drugs Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Cystic Fibrosis Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Vertex Pharmaceuticals
- 8.4.1 Vertex Pharmaceuticals Company Information
- 8.4.2 Vertex Pharmaceuticals Business Overview
- 8.4.3 Vertex Pharmaceuticals Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Vertex Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
- 8.4.5 Vertex Pharmaceuticals Recent Developments
- 8.5 Venus Remedies
- 8.5.1 Venus Remedies Company Information
- 8.5.2 Venus Remedies Business Overview
- 8.5.3 Venus Remedies Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Venus Remedies Cystic Fibrosis Drugs Product Portfolio
- 8.5.5 Venus Remedies Recent Developments
- 8.6 United Medical
- 8.6.1 United Medical Company Information
- 8.6.2 United Medical Business Overview
- 8.6.3 United Medical Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 United Medical Cystic Fibrosis Drugs Product Portfolio
- 8.6.5 United Medical Recent Developments
- 8.7 PTC Therapeutics
- 8.7.1 PTC Therapeutics Company Information
- 8.7.2 PTC Therapeutics Business Overview
- 8.7.3 PTC Therapeutics Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 PTC Therapeutics Cystic Fibrosis Drugs Product Portfolio
- 8.7.5 PTC Therapeutics Recent Developments
- 8.8 Proteostasis Therapeutics
- 8.8.1 Proteostasis Therapeutics Company Information
- 8.8.2 Proteostasis Therapeutics Business Overview
- 8.8.3 Proteostasis Therapeutics Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Proteostasis Therapeutics Cystic Fibrosis Drugs Product Portfolio
- 8.8.5 Proteostasis Therapeutics Recent Developments
- 8.9 Pharmaxis
- 8.9.1 Pharmaxis Company Information
- 8.9.2 Pharmaxis Business Overview
- 8.9.3 Pharmaxis Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Pharmaxis Cystic Fibrosis Drugs Product Portfolio
- 8.9.5 Pharmaxis Recent Developments
- 8.10 PharmaSwiss
- 8.10.1 PharmaSwiss Company Information
- 8.10.2 PharmaSwiss Business Overview
- 8.10.3 PharmaSwiss Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 PharmaSwiss Cystic Fibrosis Drugs Product Portfolio
- 8.10.5 PharmaSwiss Recent Developments
- 8.11 Novo Nordisk
- 8.11.1 Novo Nordisk Company Information
- 8.11.2 Novo Nordisk Business Overview
- 8.11.3 Novo Nordisk Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Novo Nordisk Cystic Fibrosis Drugs Product Portfolio
- 8.11.5 Novo Nordisk Recent Developments
- 8.12 Neovii Biotech
- 8.12.1 Neovii Biotech Company Information
- 8.12.2 Neovii Biotech Business Overview
- 8.12.3 Neovii Biotech Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Neovii Biotech Cystic Fibrosis Drugs Product Portfolio
- 8.12.5 Neovii Biotech Recent Developments
- 8.13 Merck Sharp & Dohme
- 8.13.1 Merck Sharp & Dohme Company Information
- 8.13.2 Merck Sharp & Dohme Business Overview
- 8.13.3 Merck Sharp & Dohme Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Merck Sharp & Dohme Cystic Fibrosis Drugs Product Portfolio
- 8.13.5 Merck Sharp & Dohme Recent Developments
- 8.14 Insmed
- 8.14.1 Insmed Company Information
- 8.14.2 Insmed Business Overview
- 8.14.3 Insmed Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Insmed Cystic Fibrosis Drugs Product Portfolio
- 8.14.5 Insmed Recent Developments
- 8.15 Gilead Sciences
- 8.15.1 Gilead Sciences Company Information
- 8.15.2 Gilead Sciences Business Overview
- 8.15.3 Gilead Sciences Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Gilead Sciences Cystic Fibrosis Drugs Product Portfolio
- 8.15.5 Gilead Sciences Recent Developments
- 8.16 Genzyme
- 8.16.1 Genzyme Company Information
- 8.16.2 Genzyme Business Overview
- 8.16.3 Genzyme Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Genzyme Cystic Fibrosis Drugs Product Portfolio
- 8.16.5 Genzyme Recent Developments
- 8.17 F. Hoffmann-La Roche
- 8.17.1 F. Hoffmann-La Roche Company Information
- 8.17.2 F. Hoffmann-La Roche Business Overview
- 8.17.3 F. Hoffmann-La Roche Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 F. Hoffmann-La Roche Cystic Fibrosis Drugs Product Portfolio
- 8.17.5 F. Hoffmann-La Roche Recent Developments
- 8.18 Corbus Pharmaceuticals
- 8.18.1 Corbus Pharmaceuticals Company Information
- 8.18.2 Corbus Pharmaceuticals Business Overview
- 8.18.3 Corbus Pharmaceuticals Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Corbus Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
- 8.18.5 Corbus Pharmaceuticals Recent Developments
- 8.19 Chiesi Farmaceutici
- 8.19.1 Chiesi Farmaceutici Company Information
- 8.19.2 Chiesi Farmaceutici Business Overview
- 8.19.3 Chiesi Farmaceutici Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Chiesi Farmaceutici Cystic Fibrosis Drugs Product Portfolio
- 8.19.5 Chiesi Farmaceutici Recent Developments
- 8.20 Boehringer Ingelheim
- 8.20.1 Boehringer Ingelheim Company Information
- 8.20.2 Boehringer Ingelheim Business Overview
- 8.20.3 Boehringer Ingelheim Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 Boehringer Ingelheim Cystic Fibrosis Drugs Product Portfolio
- 8.20.5 Boehringer Ingelheim Recent Developments
- 8.21 Arcturus Therapeutics
- 8.21.1 Arcturus Therapeutics Company Information
- 8.21.2 Arcturus Therapeutics Business Overview
- 8.21.3 Arcturus Therapeutics Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.21.4 Arcturus Therapeutics Cystic Fibrosis Drugs Product Portfolio
- 8.21.5 Arcturus Therapeutics Recent Developments
- 8.22 Anthera Pharmaceuticals
- 8.22.1 Anthera Pharmaceuticals Company Information
- 8.22.2 Anthera Pharmaceuticals Business Overview
- 8.22.3 Anthera Pharmaceuticals Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.22.4 Anthera Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
- 8.22.5 Anthera Pharmaceuticals Recent Developments
- 8.23 Actavis
- 8.23.1 Actavis Company Information
- 8.23.2 Actavis Business Overview
- 8.23.3 Actavis Cystic Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.23.4 Actavis Cystic Fibrosis Drugs Product Portfolio
- 8.23.5 Actavis Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Cystic Fibrosis Drugs Value Chain Analysis
- 9.1.1 Cystic Fibrosis Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Cystic Fibrosis Drugs Production Mode & Process
- 9.2 Cystic Fibrosis Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Cystic Fibrosis Drugs Distributors
- 9.2.3 Cystic Fibrosis Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst